Search Results for: liver cancer

How reconstructing the past hepatitis B epidemic can help prevent liver cancer in the future

Nora Schmit was shortlisted for the MRC Max Perutz Science Writing Award 2019 for the following article on her PhD research on predicting the impact of treatment for hepatitis B infection on preventing liver cancer in The Gambia.

What’s the first thing that comes to your mind when you think of cancer prevention? Maybe you’re thinking of not smoking or maintaining a healthy weight – great strategies to reduce your chance of getting cancer.

But did you know that the hepatitis B vaccine, introduced in the 1980s, has long protected children in many parts of the world from developing one of the most common and deadliest cancers later in life?

Although most people have no symptoms when they first become infected, the hepatitis B virus is the leading cause of liver cancer worldwide. Large-scale efforts to tackle the virus using vaccination have been hugely successful in preventing infections in children. Despite this remarkable achievement, hepatitis B infections are still very common and nearly a million people die from its consequences every year. With around 6% of all people living in Africa currently infected, the death toll there is expected to rise even further.

But while a liver cancer diagnosis is nearly always fatal, treating the infection is possible with the same drugs that work against HIV. So why do so few people receive these drugs, when over half of all liver cancer deaths globally are preventable? (more…)

The iKnife – the cutting-edge of cancer diagnosis?

The iKnife analysing a liver tissue sample

For all the advancements medicine has seen in recent decades, there remains a major public health challenge: cancer. However, a new surgical tool called the iKnife has shown significant promise in improving the diagnosis of endometrial (womb) cancer. Professor Sadaf Ghaem-Maghami discusses how this new tool could transform the clinical care of thousands of patients.

Endometrial (womb) cancer is the most common gynaecological cancer in the UK, and the fourth most common cancer in women. It affects 9,300 women and people with gynae organs every year in the UK alone. It generally occurs in postmenopausal women, but up to 25% of cases are diagnosed in the pre-menopause. Its main symptom is one of abnormal bleeding. These women are usually referred to the two-week wait clinics for diagnosis or exclusion of cancer.

(more…)

Blood Cancer Awareness Month: all roads lead to EVI1

PhD student Philippa May reflects on being a scientist in the field blood cancer, from working in a leukaemia diagnostic laboratory to a research laboratory. 

For the last 10 years I have been a clinical scientist in genetics working across various London NHS Trusts. Whilst I loved diagnostics, last year I left my job to complete my PhD. I worked in a part of life sciences called cytogenetics. This meant when a patient was diagnosed with blood cancer, I would analyse their chromosomes – the structures into which DNA is organised – from their blood or bone marrow to look for specific abnormalities. For some patients, this can lead to a definitive diagnosis. For others a refined prognosis, and in some, it’s simply a way of monitoring how well the patient’s leukaemia is responding to their treatment. (more…)

From Paris to London, via The Gambia—my journey as a clinician scientist

Prof Maud Lemoine with key collaborators, including Dr Yusuke Shimakawa and Dr Gibril Ndow
Prof Maud Lemoine with key collaborators, including Dr Yusuke Shimakawa and Dr Gibril Ndow

On the national day of France—known as ‘Bastille Day’ in English—we hear from Prof Maud Lemoine, Professor and Honorary Consultant in Hepatology at Imperial’s Department of Metabolism, Digestion and Reproduction. She completed her medical degree and PhD in Paris, France, before working in The Gambia, and then the UK  

What brought you to London, and Imperial?

Initially I came a bit by chance. I was working in a teaching hospital in Paris as a full-time clinical consultant, having completed a PhD in physiopathology of non-alcoholic fatty liver disease. I wanted to work abroad and was very interested in working on viral hepatitis and liver cancer in sub-Saharan Africa. I wanted to work in a non-French speaking environment and meet other cultures. In 2011, by chance, I met Prof Mark Thursz who gave me the opportunity to join his team. I spent about 2 years and a half in The Gambia where I implemented a very ambitious research programme on liver diseases in West Africa. Then, in 2014, I moved to London. I hadn’t planned to move to London, but then I discovered a different culture—where I was given so many more opportunities than I’d have in the French system. I was extremely motivated but more importantly I felt really supported by Imperial and my department to develop my ambitions and create my own research group. I do still miss the French system from which I have learnt a lot.

I was initially going to spend a year or two as a lecturer at Imperial, but then I secured more funding to expand my research activities and really enjoyed the work environment and its management based on trust and creativity—especially as it’s much more diverse here. There are so many different nationalities represented in our department, it’s really nice.

(more…)

Hope for a hepatitis B cure: the cunning virus that is outsmarting scientists

For World Hepatitis Day, Dr Ana Ortega-Prieto explains why she switched her research focus from hepatitis C to hepatitis B – a virus that continues its global spread despite an available vaccine. 

When I first started to work on hepatitis C virus (HCV) for my PhD, the general conviction was that it was a dangerous pathogen with very unsuccessful treatments. In the past years, this has completely changed; patients used to endure one year of treatment with severe side effects, but can now expect just three months of treatment, which is generally well tolerated. The truly impressive part here is that treatment success went up from below 50% to well over 90%. This has triggered the World Health Organisation (WHO) to aim for the eradication of all viral hepatitis by 2030 – a very ambitious goal. (more…)

How machine learning will transform the way we look at medical images

Machine learning

Dr Tim Hoogenboom, a Research Sonographer, looks at the promise and perils of machine learning in medical imaging.

Medical imaging is key in today’s delivery of modern healthcare, with an immense 41 million imaging tests taking place in England in every year. Thousands upon thousands of patients safely undergo imaging procedures such as X-ray, ultrasound, and MRI every day, and the product of these tests – the images – play an essential role in informing the decisions of medical professionals and patients in nearly every area of disease. (more…)

From Britpop to breakthroughs: Reflecting on 30 years of HIV testing and treatment

Born on what would eventually be recognized as World AIDS Day in the 1970s, Dr Mike Emerson, now affiliated with the National Heart and Lung Institute, relocated to vibrant London during the early 1990s amidst the fervour of the Britpop era. In the backdrop of Blur and Pulp melodies, 1990s London faced the AIDS crisis. Three decades later, he is at the helm of a team investigating cardiovascular ailments in people with HIV. In this piece, Dr Emerson reflects on the advancements in HIV diagnosis and therapy, and reiterates the ongoing importance of  National HIV Testing Week. 

I was born on what was to become World AIDS day way back in the 1970s, and moved to the big smoke in the early 90s. London was exploding with Britpop excitement, and in the absence of mobile tech, we went out every night to the sounds of Blur and Pulp. 90s London was also the epicentre of the UK’s bit of the global AIDS crisis. People in their early 20s, as I was, were dying (of ignorance the government told us). I quickly learnt not to hold birthday celebrations in Soho; celebrating and mourning young friends and sons don’t mix well. Exactly 30 years later, I lead a team investigating cardiovascular disease as people live with HIV for decades and succumb to the diseases of old age. This week is HIV testing week, so it’s a good time to reflect on how far we have come and remind ourselves of the importance of HIV testing. 

Back in 1981, a couple of obscure articles noted incidences of fatal pneumonia and rare skin cancers in otherwise healthy young American men. Oddly, these men were all gay. Within months, there was an explosion of terrifying fatal illness amongst the gay communities of New York, San Francisco and, not far behind, London. People became infected with HIV following blood transfusions, and babies were born with the condition and died. When HIV tests became available, the prospect of one was terrifying, involving a week-long wait for results and a recommendation to take a friend when results were due to be delivered. 

(more…)

Do we need such a devastating global pandemic to raise the profile of research?


On Clinical Trials Day, Fran Husson discusses how receiving treatment for Acute Myeloblastic Leukaemia made her aware of the value and impact of research.

It is impossible, as a patient, not to think “vaccination” when asked to engage in some reflection about “Research”.  Vaccines would not have been created so swiftly to combat Sars-CoV-2 if strong and well established multi-disciplinary cohorts of researchers, within prominent academic institutions, had not been in place to mastermind clinical trials and produce an effective immunisation response to the pandemic.

This begs the question of Patient and Public awareness of research, whether for clinical purposes or service delivery of health and social care.  Do we need such a devastating global pandemic to raise the profile of research?

In my case, a late diagnosis of Acute Myeloblastic Leukaemia provided the lightning bolt to make me aware of research. Hospitalised in isolation for ten months, under round-the-clock treatment from clinicians who also involved me in different clinical research projects, I could not but appreciate the full value and impact of research. (more…)

Radiation and human health – separating scientific facts from urban myths

Professor Gerry Thomas
This festive period Three Wise Women from the Faculty of Medicine will be giving us the gift of wisdom.

Our first is Professor Gerry Thomas, a leading authority on the health impacts of radiation, who tells us why we should focus on the facts.

I was born in the 1960s and grew up believing that the word ‘radiation’ meant something that was infinitely dangerous. Back then, we were led to believe that nuclear weapons would lead to the extinction of our species, and that to be bitten by a radioactive spider would confer supernatural powers! I was therefore sceptical about the use of nuclear power. It wasn’t until 1992, when I started to study the health effects of the accident at the Chernobyl nuclear power station in 1986, that I began to question whether my understanding of the health effects of radiation came more from science fiction than scientific fact. (more…)

A smoke-free country: how will we get there?

The Government recently announced plans to create a smoke-free society by 2030 – Dr Nick Hopkinson outlines some of the steps towards achieving this ambition.

Tobacco smoking remains a huge public health issue. Although population smoking rates continue to fall – now down to 14.4% of adults – smoking is still responsible for around 100,000 deaths per year in the UK, and for around half the difference in life expectancy between rich and poor. Smoking rates are high in areas of deprivation, in people with mental health problems and among people who identify as LGBT.

The Government’s recent green paper, Advancing our health: prevention in the 2020’s, although in many areas light on detail, funding, delivery and ambition, does set out some important markers on smoking and some potentially interesting developments around funding tobacco control. (more…)